Clinical experience of using formoterol/budesonide in patients with chronic obstructive pulmonary disease

Clinical experience of using formoterol/budesonide in patients with chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) today remains one of the most important problems of modern medicine. The social significance of this disease is determined by the annual health care costs for treating patients with exacerbated COPD, as well as the still high mortality and disability rate...

Full description

Bibliographic Details
Main Authors:	I. V. Demko, M. G. Mamaeva, E. A. Sobko, A. Yu. Kraposhina, N. V. Gordeeva
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2021-10-01
Series:	Медицинский совет
Subjects:	chronic obstructive pulmonary disease exacerbation blood eosinophils long-acting bronchodilators inhaled corticosteroids budesonide/formoterol
Online Access:	https://www.med-sovet.pro/jour/article/view/6456

Similar Items

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting
by: Perrone V, et al.
Published: (2016-11-01)

Some aspects of application of the combination of formoterol and budesonide: what is changed?
by: A. A. Vizel, et al.
Published: (2019-12-01)

Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain
by: Trigueros JA, et al.
Published: (2022-11-01)

An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing
by: L Meyer, et al.
Published: (2003-05-01)

Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey
by: Miravitlles M, et al.
Published: (2022-07-01)

Experience with the triple fixed combination in patients with chronic obstructive pulmonary disease
by: I. V. Demko, et al.
Published: (2022-01-01)

Comparative Efficacy of Budesonide/Formoterol Versus Fluticasone/Salmeterol in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
by: Nan Shang, et al.
Published: (2024-12-01)

Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study
by: David B. Price, et al.
Published: (2018-06-01)

A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease
by: Omar Usmani, et al.
Published: (2021-10-01)

An Indian perspective on the use of fluticasone/formoterol in asthma and chronic obstructive pulmonary disease patients
by: Rahul Sharma, et al.
Published: (2021-01-01)

Is It Really Feasible to Use Budesonide–Formoterol as Needed for Mild Persistent Asthma? A Systematic Review and Meta-Analysis
by: Xiang Tong, et al.
Published: (2021-06-01)

Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis
by: Tang B, et al.
Published: (2019-04-01)

Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
by: Tashkin DP
Published: (2020-11-01)

Effects of treatment with montelukast alone, budesonide/formoterol alone and a combination of both in cough variant asthma
by: Fang Yi, et al.
Published: (2022-10-01)

Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history
by: Shigeo Muro, et al.
Published: (2024-08-01)

New combinations in the treatment of COPD: rationale for aclidinium–formoterol
by: Incorvaia C, et al.
Published: (2016-02-01)

Comparison of Risk of Pneumonia Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study
by: Choi JH, et al.
Published: (2021-11-01)

Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study
by: Strange C, et al.
Published: (2023-10-01)

Optimization of Nebulized Budesonide in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
by: Zhang R, et al.
Published: (2020-02-01)

Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study [Corrigendum]
by: Strange C, et al.
Published: (2024-08-01)

Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap
by: Ishiura Y, et al.
Published: (2020-02-01)

Chronic obstructive pulmonary disease – A neglected and underestimated chronic lung disease in India: A large single-center study in India
by: Shital Patil, et al.
Published: (2023-01-01)

Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases.
by: María del Carmen Cano-Salas, et al.
Published: (2024-12-01)

The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study
by: Hsieh MJ, et al.
Published: (2018-09-01)

Effectiveness and Patient Satisfaction with Budesonide/Formoterol Easyhaler® Among Patients with Asthma or COPD Switching from Previous Treatment: a Real-World Study of Patient-Reported Outcomes
by: Gabriella Gálffy, et al.
Published: (2019-07-01)

Exacerbation and Cardiovascular Events in Eosinophilic Chronic Obstructive Pulmonary Disease
by: Mami Orimo, et al.
Published: (2023-04-01)

Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS
by: Muro S, et al.
Published: (2024-12-01)

Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial
by: Ana Luisa Godoy Fernandes, et al.
Published: (2001-09-01)

Pharmacological therapy for stable chronic obstructive pulmonary disease
by: Ruirui Duan, et al.
Published: (2023-06-01)

Adherence and quality of life assessment in patients with asthma treatment with budesonide/formoterol via the Elpenhaler device: the COMPLETE study
by: Konstantinos P. Exarchos, et al.
Published: (2022-06-01)

Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long-acting β2-agonists/long-acting muscarinic antagonists
by: Nevin Kishore, et al.
Published: (2020-01-01)

Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study
by: de Nigris E, et al.
Published: (2022-11-01)

Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy
by: Dhungana S, et al.
Published: (2017-08-01)

Pharmacotherapy of chronic obstructive pulmonary disease: Therapeutic considerations with a focus on inhaled corticosteroids
by: Elvis M. Irusen, et al.
Published: (2020-12-01)

Effect of Switching from Salmeterol/Fluticasone to Formoterol/Budesonide Combinations in Patients with Uncontrolled Asthma
by: Taisuke Akamatsu, et al.
Published: (2012-01-01)

Risk of pneumonia with budesonide-containing treatments in COPD: an individual patient-level pooled analysis of interventional studies
by: Hollis S, et al.
Published: (2017-04-01)

Comparison of efficacy between long-acting beta 2-agonists (formoterol fumarate) and leukotriene-receptor antagonists (montelukast) as add-on therapy to inhaled corticosteroids (budesonide) in moderate persistent asthma
by: Sasikala Kumaravel, et al.
Published: (2014-01-01)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
by: Maarten van den Berge, et al.
Published: (2021-07-01)

Effect of fluticasone propionate/formoterol and fluticasone furoate/vilanterol on adolescents with chronic bronchial obstruction
by: Tiina Helena Tanninen, MD, et al.
Published: (2024-08-01)

New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease
by: S N Avdeev, et al.
Published: (2019-03-01)